10x Genomics (TXG) Asset Writedowns and Impairment (2023 - 2025)

10x Genomics' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $114000.0 for Q1 2025.

• In Q1 2025, Asset Writedowns and Impairment fell 95.35% year-over-year to $114000.0; the TTM figure through Mar 2026 stood at $114000.0 (down 84.03% YoY), while the FY2025 annual figure was $814000.0, down 73.35% from the prior year.
• Asset Writedowns and Impairment came in at $114000.0 for Q1 2025 at 10x Genomics, down from $600000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $7.1 million in Q4 2023 to a low of $114000.0 in Q1 2025.
• A 3-year average of $2.6 million and a median of $2.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment plunged 91.5% in 2024 and sank 95.35% in 2025, its largest moves.
• 10x Genomics' Asset Writedowns and Impairment stood at $7.1 million in 2023, then slumped by 91.5% to $600000.0 in 2024, then sank by 81.0% to $114000.0 in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $114000.0, $600000.0, and $2.5 million for Q1 2025, Q4 2024, and Q1 2024 respectively.

Peer Comparison